Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

NCT02780804 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02780804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02780804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
January 6, 2017
Completion date
September 30, 2021
Enrollment
21 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

brain stem neoplasm, pineal region neoplasm, recurrent lymphoma, recurrent malignant solid neoplasm, recurrent primary central nervous system neoplasm, recurrent visual pathway glioma, refractory lymphoma, refractory malignant solid neoplasm, refractory primary central nervous system neoplasm, refractory visual pathway glioma